Abstract 459P
Background
Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer death among males and females. There is evidence that diet habit may influence lung cancer risk. To determine the association between fish intake and dietary polyunsaturated fatty acids (PUFA) and incidence of lung cancer, we identified all available studies to clarify the dose-response relationship between fish and PUFA and lung cancer risk, evaluated the potential effects of frequent fish and PUFA intake on lung cancer mortality, and studied the ability of their supplementations during chemotherapy in patients with lung cancer.
Methods
We systematically reviewed and meta-analyzed the published studies in MEDLINE, EMBASE databases, Cochrane Library database (Cochrane central register of controlled trials) and ClinicalTrials, supplemented with manual screening. Large-scale prospective cohort study and randomized control trials quantifying the associations of fish and PUFA consumption with risk of lung cancer were included. Two investigators dependently assessed studies for inclusion and extracted data on methods, interventions, outcomes and study quality. Relative risk (RR) with 95% confidence interval (CI) was calculated.
Results
13 population-based prospective cohort studies involving 1,785,000 participants and 2 randomized control trials were included. Our study demonstrated that dietary PUFA significant reduced risk of lung cancer for men (RR 0.99, 95%CI 0.98 to 1.00) and USA population (RR 0.99, 95%CI 0.98 to 1.00). Dose-response analysis indicated that a 5g/day increment of dietary PUFA was associated with 5% lower risk of lung cancer (RR 0.95, 95%CI 0.91 to 0.99). In addition, PUFA supplementation is significant improved overall survival in patients with lung cancer (RR 1.98, 95%CI 1.09 to 3.59).
Conclusions
Our study showed an inverse association between dietary PUFA and risk of lung cancer in males and among USA population. Although smoking cessation is the single biggest factor associated with lung cancer risk reduction, this study adds to a growing body of evidence that diet may have a role in modestly reducing lung cancer risk.
Clinical trial identification
Editorial acknowledgement
This work was supported by program for the National Natural Science Foundation of China (grant number 81700025), the Medical and Health Science and Technology Project of Zhejiang (grant number 2018245859), the Medical Science and Technology Plan Projects of Ningbo (grant number 2016A03), the Science Foundation of Zhejiang (grant number LY15H010002) and the Beijing Medical Health Foundation (grant number YWJKJJHKYJJ-HX32).
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
174P - Progression of computer aided diagnosis on gastric cancer
Presenter: Yingyan Yu
Session: Poster display session
Resources:
Abstract
175P - Hypermethylation of the PCDHB15 promoter predicts the prognosis in gastric cancer
Presenter: Yu-ting Lee
Session: Poster display session
Resources:
Abstract
176P - DCLK1 promotes tumour invasion and metastasis through epithelial-mesenchymal transition and the MEK/ERK pathway in esophageal squamous cell carcinoma
Presenter: Jiannan Yao
Session: Poster display session
Resources:
Abstract
177P - Comparison of nab-paclitaxel plus ramcirumab and paclitaxel plus ramcirumab in patients with pretreated metastatic gastric cancer
Presenter: Yosuke Horita
Session: Poster display session
Resources:
Abstract
178P - Chief cell in stomach have stem cell activity and potential to develop gastric cancer
Presenter: Akihiro Yamamura
Session: Poster display session
Resources:
Abstract
179P - Postoperative Adjuvant transarterial chemoembolization versus surgery alone for resected hepatocellular carcinoma: A propensity-score matching study
Presenter: Mingyu Chen
Session: Poster display session
Resources:
Abstract
180P - LHPP inhibit the cell proliferation and EMT via the TGFβ/SMAD3 signaling pathway in iCCA
Presenter: Dan Wang
Session: Poster display session
Resources:
Abstract
181P - The emerging role of third-line gemcitabine plus nab-paclitaxel in advanced pancreatic adenocarcinoma
Presenter: Andrew Dean
Session: Poster display session
Resources:
Abstract
182P - Durable response to second-line m-FOLFIRINOX for advanced pancreatic adenocarcinoma in patients with performance status of two or less
Presenter: Adarsh Das
Session: Poster display session
Resources:
Abstract
183P - Epidemiologic profile of gastric cancer in East Azerbaijan, Iran: 2 years population-based cancer registry results
Presenter: Pooneh Jabbaripour
Session: Poster display session
Resources:
Abstract